Marinomed
About Marinomed
Marinomed is a biopharmaceutical development company focusing on the development of innovative therapies based on patent protected technology platforms. Products against respiratory viruses derived from the proprietary MAVIREX platform are marketed with renowned partners in a growing number of countries around the globe. The new MARINOSOLV platform allows novel stable aqueous formulations of hardly soluble compounds such as corticosteroids, enabling a faster onset of action and a better bioavailability. The MARINOSOLV technology is not limited to a specific compound and has the potential to facilitate delivery of any compound with solubility issues. Marinomed was founded on 2006 and is headquartered in Vienna, Austria.
Company Metrics
- Employees: 11-50
- Monthly Visits: 762
- Tech Stack: None active products
Financial Information
- Estimated Revenue:
- Total Funding: 6956638 USD
- Last Funding: 5400000 USD (Convertible Note)
- Funding Status: Private Equity
Technology Stack
Marinomed actively uses None products in their tech stack.
Market Presence
Industries: Biopharma, Biotechnology, Health Care, Medical, Product Design, Therapeutics
Headquarters: Vienna, Wien, Austria